These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3099116)

  • 41. Inactivation of alpha-glucosidase by the active-site-directed inhibitor, conduritol B epoxide.
    Yang SJ; Ge SG; Zeng YC; Zhang SZ
    Biochim Biophys Acta; 1985 Apr; 828(3):236-40. PubMed ID: 3886011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Soluble and membranous neutral beta-glucosidases.
    Ben-Yoseph Y; Nadler HL
    Prog Clin Biol Res; 1982; 95():465-80. PubMed ID: 6812082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Beta-glucosidase 2 knockout mice with increased glucosylceramide show impaired liver regeneration.
    Gonzalez-Carmona MA; Sandhoff R; Tacke F; Vogt A; Weber S; Canbay AE; Rogler G; Sauerbruch T; Lammert F; Yildiz Y
    Liver Int; 2012 Oct; 32(9):1354-62. PubMed ID: 22764777
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
    Hamler R; Brignol N; Clark SW; Morrison S; Dungan LB; Chang HH; Khanna R; Frascella M; Valenzano KJ; Benjamin ER; Boyd RE
    Anal Chem; 2017 Aug; 89(16):8288-8295. PubMed ID: 28686011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conduritol aziridine: a new mechanism-based glucosidase inactivator.
    Caron G; Withers SG
    Biochem Biophys Res Commun; 1989 Aug; 163(1):495-9. PubMed ID: 2673241
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide.
    Bodennec J; Pelled D; Riebeling C; Trajkovic S; Futerman AH
    FASEB J; 2002 Nov; 16(13):1814-6. PubMed ID: 12223447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biliary excretion of glycolipid in induced or inherited glucosylceramide lipidosis.
    Pentchev PG; Gal AE; Wong R; Morrone S; Neumeyer B; Massey J; Kanter R; Sawitsky A; Brady RO
    Biochim Biophys Acta; 1981 Sep; 665(3):615-8. PubMed ID: 7295755
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of the phospholipid requirement of a rat liver beta-glucosidase.
    Basu A; Glew RH
    Biochem J; 1984 Dec; 224(2):515-24. PubMed ID: 6517862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Studies of the pathogenesis of Gaucher's disease: tissue distribution and biliary excretion of [14C]L-glucosylceramide in rats.
    Tokoro T; Gal AE; Gallo LL; Brady RO
    J Lipid Res; 1987 Aug; 28(8):968-72. PubMed ID: 3668390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Control of kidney size by sex hormones: possible involvement of glucosylceramide.
    Shukla A; Shukla GS; Radin NS
    Am J Physiol; 1992 Jan; 262(1 Pt 2):F24-9. PubMed ID: 1733293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Galactosylsphingosine inhibition of the broad-specificity cytosolic beta-glucosidase of human liver.
    LaMarco KL; Glew RH
    Arch Biochem Biophys; 1985 Feb; 236(2):669-76. PubMed ID: 3918500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin trafficking.
    Sun Y; Witte DP; Zamzow M; Ran H; Quinn B; Matsuda J; Grabowski GA
    Hum Mol Genet; 2007 Apr; 16(8):957-71. PubMed ID: 17353235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assay of β-glucosidase 2 (GBA2) activity using lithocholic acid β-3-O-glucoside substrate for cultured fibroblasts and glucosylceramide for brain tissue.
    Harzer K; Yildiz Y; Beck-Wödl S
    Biol Chem; 2019 May; 400(6):745-752. PubMed ID: 30864417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Variable expression of leukocyte cytosolic broad-specificity beta-glucosidase activity.
    Forsyth GW; Romero KM; Alverson J; VanderJagt DJ; Glew RH
    Clin Chim Acta; 1993 Jul; 216(1-2):11-21. PubMed ID: 8222261
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human acid beta-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme's catalytic mechanism and saposin A and C binding sites.
    Fabbro D; Grabowski GA
    J Biol Chem; 1991 Aug; 266(23):15021-7. PubMed ID: 1714449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A rat brain cytosol protein which accelerates the translocation of galactosylceramide, lactosylceramide and glucosylceramide between membranes.
    Yamada K; Sasaki T
    Biochim Biophys Acta; 1982 May; 687(2):195-203. PubMed ID: 7093250
    [No Abstract]   [Full Text] [Related]  

  • 57. Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease.
    Grabowski GA; Gatt S; Horowitz M
    Crit Rev Biochem Mol Biol; 1990; 25(6):385-414. PubMed ID: 2127241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The inhibition of glucosylceramide beta-glucosidase and other acid hydrolases by nucleic acids.
    Sano A; Radin NS
    Biochem J; 1988 Aug; 254(1):297-300. PubMed ID: 2460090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biochemical studies in a patient with subacute neuropathic Gaucher disease without visceral glucosylceramide storage.
    Wenger DA; Roth S; Kudoh T; Grover WD; Tucker SH; Kaye EM; Ullman MD
    Pediatr Res; 1983 May; 17(5):344-8. PubMed ID: 6856396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. L-glucosylceramide: synthesis, properties, and resistance to catabolism by glucocerebrosidase in vitro.
    Gal AE; Pentchev PG; Massey JM; Brady RO
    Proc Natl Acad Sci U S A; 1979 Jul; 76(7):3083-6. PubMed ID: 290986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.